About

Jeffrey Farrow has served as an Achieve Life Sciences director since 2026, chairing the Audit Committee and serving on the Nominating and Governance Committee. He has been Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals since April 2023 and previously served as Chief Financial Officer of Global Blood Therapeutics (2016-2022, acquired by Pfizer), ZS Pharma (acquired by AstraZeneca in 2015) and Hyperion Therapeutics (acquired by Horizon Therapeutics in 2015), and earlier as vice president of finance at Evotec AG and vice president of finance and Chief Accounting Officer at Renovis, Inc. He began his career in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration from California State University at Fullerton and is a certified public accountant (inactive).

Roles

Achieve Life Sciences, Inc.
Director (Chair, Audit Committee) · Current role
2026–present
Tarsus Pharmaceuticals, Inc.
Chief Financial Officer and Chief Strategy Officer
2023 - present
Global Blood Therapeutics, Inc.
Chief Financial Officer · Acquired by Pfizer
2016 - 2022
ZS Pharma, Inc.
Chief Financial Officer · Acquired by AstraZeneca in 2015
—
Hyperion Therapeutics, Inc.
Chief Financial Officer · Acquired by Horizon Therapeutics
2010 - 2015
KPMG LLP
Audit practice
—

External Roles

Clover Biotherapeutics
Board member
2021 - present

Also at Achieve Life Sciences, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.